TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux
Brief Summary: The study prospectively compares two treatment algorithms for newly diagnosed Crohn's disease: one 'aggressive' treatment with early introduction of immunomodulators and biologicals and one 'standard treatment' with corticosteroids and only later introduction of immunosuppressives and biologicals if disease activity requires that.


Options:
A: Arm Label: PRECISION dosing; Type: EXPERIMENTAL; Interventions: Drug: PRECISION dosing Infliximab | Arm Label: Conventional dosing of Infliximab; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: PRECISION dosing Infliximab; Assigned to Arm(s): PRECISION dosing
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Measurement of serum infliximab and anti-infliximab antibodies | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status | Intervention Type: PROCEDURE; Name: Measurement of serum infliximab and anti-infliximab antibodies; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status; Assigned to Arm(s): 2
C: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Biological: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux
Brief Summary: The study prospectively compares two treatment algorithms for newly diagnosed Crohn's disease: one 'aggressive' treatment with early introduction of immunomodulators and biologicals and one 'standard treatment' with corticosteroids and only later introduction of immunosuppressives and biologicals if disease activity requires that.


Options:
A: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2
D: Arm Label: Rituximab Intravenous Infusion; Type: EXPERIMENTAL; Interventions: Drug: Anti-CD20 (rituximab) | Arm Label: Placebo Intravenous Infusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Anti-CD20 (rituximab); Assigned to Arm(s): Rituximab Intravenous Infusion | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo Intravenous Infusion

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux
Brief Summary: The study prospectively compares two treatment algorithms for newly diagnosed Crohn's disease: one 'aggressive' treatment with early introduction of immunomodulators and biologicals and one 'standard treatment' with corticosteroids and only later introduction of immunosuppressives and biologicals if disease activity requires that.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: infliximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Double Blind; Type: PLACEBO_COMPARATOR; Interventions: Biological: adalimumab, Biological: placebo | Arm Label: Open Label; Type: OTHER; Interventions: Biological: adalimumab | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Double Blind | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Open Label
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2
D: Arm Label: Active arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: endoscopy | Arm Label: Standard care arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: endoscopy; Assigned to Arm(s): Active arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux
Brief Summary: The study prospectively compares two treatment algorithms for newly diagnosed Crohn's disease: one 'aggressive' treatment with early introduction of immunomodulators and biologicals and one 'standard treatment' with corticosteroids and only later introduction of immunosuppressives and biologicals if disease activity requires that.


Options:
A: Arm Label: control = conventional treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Immunossuppresive treatment; Type: EXPERIMENTAL; Interventions: Drug: early immunosuppressants (azathioprine, methotrexate) | Intervention Type: DRUG; Name: early immunosuppressants (azathioprine, methotrexate); Assigned to Arm(s): Immunossuppresive treatment
B: Arm Label: Azathioprine; Type: EXPERIMENTAL; Interventions: Drug: Azathioprine, Drug: Mesalazine placebo | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine, Drug: Azathioprine placebo | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Azathioprine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Azathioprine placebo; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Mesalazine placebo; Assigned to Arm(s): Azathioprine
C: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Ideal Management of Crohn's Disease: Top Down Versus Step Up Strategies. A Prospective Controlled Trial in the Benelux
Brief Summary: The study prospectively compares two treatment algorithms for newly diagnosed Crohn's disease: one 'aggressive' treatment with early introduction of immunomodulators and biologicals and one 'standard treatment' with corticosteroids and only later introduction of immunosuppressives and biologicals if disease activity requires that.


Options:
A: Arm Label: 003; Type: EXPERIMENTAL; Interventions: Other: infliximab (IFX) infusion; azathioprine (AZA) caps | Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Biological: infliximab infusion; AZA placebo caps | Intervention Type: BIOLOGICAL; Name: infliximab infusion; AZA placebo caps; Assigned to Arm(s): 002 | Intervention Type: OTHER; Name: infliximab (IFX) infusion; azathioprine (AZA) caps; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Assigned to Arm(s): 001
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: infliximab+azathioprine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylprednisolone or budesonide | Intervention Type: DRUG; Name: infliximab+azathioprine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: methylprednisolone or budesonide; Assigned to Arm(s): 2
C: Arm Label: Usual Care practice; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment Algorithm; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment Algorithm for Crohn's Disease | Intervention Type: OTHER; Name: Treatment Algorithm for Crohn's Disease; Assigned to Arm(s): Treatment Algorithm
D: Arm Label: CT-P13 - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13 | Arm Label: CT-P13 - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: CT-P13, Biological: Remicade | Arm Label: Remicade - Remicade; Type: ACTIVE_COMPARATOR; Interventions: Biological: Remicade | Arm Label: Remicade - CT-P13; Type: EXPERIMENTAL; Interventions: Biological: CT-P13, Biological: Remicade | Intervention Type: BIOLOGICAL; Name: CT-P13; Assigned to Arm(s): CT-P13 - CT-P13, CT-P13 - Remicade, Remicade - CT-P13 | Intervention Type: BIOLOGICAL; Name: Remicade; Assigned to Arm(s): CT-P13 - Remicade, Remicade - CT-P13, Remicade - Remicade

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia
Brief Summary: The purpose of this proposed pilot study is to examine the use of varenicline in people with schizophrenia to specifically assess tolerability and efficacy for smoking cessation. Specifically, The primary objective of this pilot study is to determine if taking of varenicline along with an individual smoking cessation supportive program is a safe and effective treatment of nicotine addiction in schizophrenic patients. We hypothesize that the varenicline treated patients will achieve higher rates of smoking cessation than those who receive placebo and individual support.


Options:
A: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
B: Arm Label: Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Behavioral: Behavioural support | Arm Label: Patch and nicotine-free e-cigarette; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Device: e-cigarette, Behavioral: Behavioural support | Arm Label: Patch and nicotine e-cigarette; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patch, Device: e-cigarette, Drug: Nicotine, Behavioral: Behavioural support | Intervention Type: DRUG; Name: Nicotine patch; Assigned to Arm(s): Patch, Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette | Intervention Type: DEVICE; Name: e-cigarette; Assigned to Arm(s): Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette | Intervention Type: DRUG; Name: Nicotine; Assigned to Arm(s): Patch and nicotine e-cigarette | Intervention Type: BEHAVIORAL; Name: Behavioural support; Assigned to Arm(s): Patch, Patch and nicotine e-cigarette, Patch and nicotine-free e-cigarette
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chantix, Behavioral: Standard Counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Adherence Counseling, Behavioral: Standard Counseling | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Adherence Counseling; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Standard Counseling; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia
Brief Summary: The purpose of this proposed pilot study is to examine the use of varenicline in people with schizophrenia to specifically assess tolerability and efficacy for smoking cessation. Specifically, The primary objective of this pilot study is to determine if taking of varenicline along with an individual smoking cessation supportive program is a safe and effective treatment of nicotine addiction in schizophrenic patients. We hypothesize that the varenicline treated patients will achieve higher rates of smoking cessation than those who receive placebo and individual support.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia
Brief Summary: The purpose of this proposed pilot study is to examine the use of varenicline in people with schizophrenia to specifically assess tolerability and efficacy for smoking cessation. Specifically, The primary objective of this pilot study is to determine if taking of varenicline along with an individual smoking cessation supportive program is a safe and effective treatment of nicotine addiction in schizophrenic patients. We hypothesize that the varenicline treated patients will achieve higher rates of smoking cessation than those who receive placebo and individual support.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chantix, Behavioral: Standard Counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Behavioral: Adherence Counseling, Behavioral: Standard Counseling | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Adherence Counseling; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Standard Counseling; Assigned to Arm(s): 1, 2
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia
Brief Summary: The purpose of this proposed pilot study is to examine the use of varenicline in people with schizophrenia to specifically assess tolerability and efficacy for smoking cessation. Specifically, The primary objective of this pilot study is to determine if taking of varenicline along with an individual smoking cessation supportive program is a safe and effective treatment of nicotine addiction in schizophrenic patients. We hypothesize that the varenicline treated patients will achieve higher rates of smoking cessation than those who receive placebo and individual support.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Varenicline | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Sugar pill
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline tartrate | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion hydrochloride | Arm Label: Nicotine Replacement Therapy Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Replacement Therapy Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: varenicline tartrate; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: Nicotine Replacement Therapy Patch; Assigned to Arm(s): Nicotine Replacement Therapy Patch
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Belatacept as First Line Immunosuppression in De Novo Liver Transplant Recipients
Brief Summary: The purpose of this clinical research study is to evaluate the effects of belatacept, relative to tacrolimus, on the incidence of rejection, graft loss and death in subjects receiving a liver transplant


Options:
A: Arm Label: EVR/TAC; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Tacrolimus, Drug: Corticosteroids | Arm Label: TAC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): EVR/TAC | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): EVR/TAC, TAC | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): EVR/TAC, TAC
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Sirolimus | Intervention Type: DRUG; Name: CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sirolimus; Assigned to Arm(s): 2
C: Arm Label: Group 1: Basiliximab+Belatacept (MI) + MMF; Type: EXPERIMENTAL; Interventions: Drug: Basiliximab, Drug: Belatacept More Intensive (MI), Drug: Mycophenolate Mofetil (MMF) | Arm Label: Group 2: Belatacept (MI) + MMF; Type: EXPERIMENTAL; Interventions: Drug: Belatacept More Intensive (MI), Drug: Mycophenolate Mofetil (MMF) | Arm Label: Group 3: Belatacept Less Intensive (LI) + MMF; Type: EXPERIMENTAL; Interventions: Drug: Belatacept Less Intensive (LI), Drug: Mycophenolate Mofetil (MMF) | Arm Label: Group 4: Tacrolimus + MMF; Type: OTHER; Interventions: Drug: Tacrolimus, Drug: Mycophenolate Mofetil (MMF) | Arm Label: Group 5: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Group 4: Tacrolimus + MMF, Group 5: Tacrolimus | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Group 1: Basiliximab+Belatacept (MI) + MMF | Intervention Type: DRUG; Name: Belatacept More Intensive (MI); Assigned to Arm(s): Group 1: Basiliximab+Belatacept (MI) + MMF, Group 2: Belatacept (MI) + MMF | Intervention Type: DRUG; Name: Belatacept Less Intensive (LI); Assigned to Arm(s): Group 3: Belatacept Less Intensive (LI) + MMF | Intervention Type: DRUG; Name: Mycophenolate Mofetil (MMF); Assigned to Arm(s): Group 1: Basiliximab+Belatacept (MI) + MMF, Group 2: Belatacept (MI) + MMF, Group 3: Belatacept Less Intensive (LI) + MMF, Group 4: Tacrolimus + MMF
D: Intervention Type: DRUG; Name: ATG (Fresenius Biotech); Assigned to Arm(s): N/A

Answer: C